AzTrials
AzTrials

Paroxysmal Atrial FibrillationNCT05296824

Cryoballoon PVI With PWI Versus PVI Alone In Patients With PAF

An observational study of Paroxysmal Atrial Fibrillation, run by Sacramento EP Research at 4 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Cryoballoon ablation has emerged as a safe and effective strategy for treatment of atrial fibrillation (AF) for which it has recently received a 'first-line' therapy indication by the FDA. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Paroxysmal Atrial Fibrillation
What is being tested?
Cryoballoon ablation for the treatment of atrial fibrillation
Type of treatment
Surgery or procedure
How many people
320 participants
Where
4 sitesUnited States
Study dates
1 Jan 2014to 31 Dec 2021
Phase
Observational
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Patients with symptomatic paroxysmal atrial fibrillation

Who may be able to join

  • Age 18 years or older
  • Cryoballoon PVI+PWI
  • Cryoballoon PVI alone
  • Symptomatic paroxysmal atrial fibrillation

Who cannot join

  • None

Trial locations and contacts

4 sites in 1 country.

United States4 sites
  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215

  • University of Texas Health Science Center at Houston

    Houston, Texas, 77030

  • UC Health Medical Center

    Loveland, Colorado, 80538

  • Mercy General Hospital and Dignity Health Heart and Vascular Institute

    Sacramento, California, 95819

Other trials in United States

About this study

Official title: Cryoballoon Isolation of Combined Posterior Wall and Pulmonary Veins Versus Pulmonary Veins Alone for the Treatment of Paroxysmal Atrial Fibrillation (IMPPROVE-PAF)

Cryoballoon ablation has emerged as a safe and effective strategy for treatment of atrial fibrillation (AF) for which it has recently received a 'first-line' therapy indication by the FDA. Pulmonary vein (PV) isolation (PVI) has been the cornerstone of this procedure achieving freedom from recurrent AF in up to ~80% of patients at 12 months of follow-up. However, the success has been shown to be significantly lower, in the range of 50-60% at 3-5 years of follow-up. Other more recent cryoballoon ablation studies have demonstrated marked improvements in clinical outcomes associated with concomitant PVI and cryoballoon ablation/isolation of the 'PV component' (a region of the left atrial posterior [back] wall lying between the PVs that is anatomically and embryologically related to the PVs), versus PVI alone in patients with persistent AF.

PVI+PWI using cryoballoon ablation has been widely-practiced in patients with paroxysmal AF. However, the acute/long-term safety and efficacy of this approach has not been formally investigated in paroxysmal AF. Given the mechanistic similarities between persistent and paroxysmal AF, the investigators hypothesize that similar benefits associated with PVI+PWI may also be observed in those with paroxysmal AF. Yet, due to the relative infrequency of breakthrough/recurrent arrhythmias in patients with PAF, to detect a significant difference, large sample sizes and extended follow-up (>24 months) are likely needed. Hence, the aim of this retrospective, observational study is to examine the acute and long-term efficacy and safety beyond 36 months of follow-up associated with PVI alone versus PVI+PWI using cryoballoon ablation in a large cohort of patients with PAF, performed by a single operator between 1/1/2014 and 8/31/2018 at Mercy General Hospital.

Read the detailed description

INTRODUCTION AND RATIONALE Cryoballoon ablation has emerged as a safe and effective strategy for the treatment of atrial fibrillation (AF), and based on growing evidence, it recently received an initial rhythm control strategy ('first-line' therapy) indication by the Food and Drug Administration. Pulmonary vein (PV) isolation (PVI) guided typically by cryoballoon PV occlusion remains the cornerstone of cryoballoon ablation. Although single-procedure freedom from recurrent AF following such an approach has been reported to be as high as 82% at 12 months, the success appears to be markedly diminished in the range of 50-60% during long-term follow-up. This in part may be related to the inherent limitations of cryoballoon ablation which often yields an ostial (distal) level PVI. Along these lines, prior investigations have found wide-area antral PVI encompassing the PV component (i.e., the region of the posterior wall lying between the PVs) to be superior to ostial PVI. Other more recent studies involving the cryoballoon have demonstrated marked improvements in clinical efficacy associated with concomitant PVI and posterior wall isolation (PWI) within the region of the PV component as compared to PVI alone, in patients with persistent AF. Though widely-practiced, this approach has not been formally investigated in patients with symptomatic paroxysmal AF (PAF). Given the mechanistic similarities between persistent and PAF, the investigators hypothesize that similar benefits may also be observed with PVI+PWI in the patients with PAF. Yet, given the relative infrequency of breakthrough/recurrent arrhythmias in patients with PAF, to detect a significant difference, large sample sizes and extended follow-up (>24 months) are likely needed. Hence, the aim of this retrospective, observational study is to examine the clinical efficacy and safety of PVI alone versus PVI+PWI using cryoballoon ablation, in a large cohort of patients with symptomatic PAF beyond 36 months of follow-up.

EMBRYOLOGIC EVIDENCE The PV component of the posterior left atrial wall shares a common primordial origin with the PVs. The embryologic origin of the four PVs and the PV component can be traced back to the mediastinal myocardium derived from a mid-pharyngeal strand at 6 weeks of gestation. Early on during development, a single primitive vein returns blood from the lungs to the common trabeculated atrium. As the interatrial septum forms, the single vein divides twice to give rise to the four PVs. As the PV ostia migrate away from one another, the smooth tissue of the posterior left atrial wall forms. Although this region is anatomically contiguous with the surrounding trabeculated tissue from the primitive left atrium, its embryologic origin results in electrophysiologic properties that are more similar to the muscular PV sleeves than the immediately adjacent atrial roof or floor ('true' posterior wall).

During embryogenesis, the single vein and its surrounding tissue (in addition to the Bachmann's bundle and sinus venosus-derived structures) demonstrate the expression of genes responsible for development of cardiac conduction system. Although expression of these genes decreases during embryogenesis, it is hypothesized that their continued low-level expression may explain why certain regions within the atria are more commonly the site of origin of focal ectopy. These embryologic characteristics would certainly explain the well-accepted clinical observation that AF is frequently initiated by ectopic beats arising from the PVs and the increasingly reported observation that ectopic beats from the left atrial posterior wall can similarly initiate AF.

ANATOMIC EVIDENCE A visual examination of the PV component and the orientation of its myofibrils suggests direct continuity between this region and the PV antra as does a gross anatomical assessment of certain left atrial morphologies. Meanwhile, underneath the smooth endocardial surface of the PV component, numerous subendocardial and subepicardial muscular bundles traverse with varying fiber orientation. Fibers immediately surrounding the PVs typically encircle the veins, whereas those in the subepicardial aspect of the posterior wall are comprised of the septo-pulmonary bundle and display a more vertical or oblique orientation. Immediately adjacent to the lateral aspect of the septo-pulmonary bundle are found transversely oriented fibers which extend to the left PV ostia. It is this change in orientation that is believed to promote anisotropic conduction and therefore reentry.

Prior investigators have found that in patients with PAF, this juxtaposition of fiber orientations was associated with isochronal crowding and functional block depending on the direction of wave front propagation during sinus or paced rhythm. Similarly, mapping of fibrillatory waves during cardiac surgery in patients with AF has revealed simultaneous propagation of longitudinally dissociated fibrillation waves which are separated by continuously changing lines of block. These lines of block are once again most densely packed in the PV component, leading to the highest degree of block and dissociation and the lowest incidence of wave front boundaries formed by collision.

ELECTROPHYSIOLOGIC EVIDENCE As discussed, the PV component is derived from tissues other than the primitive cardiac tube. Hence, the PV component is believed to be related more to PV versus atrial tissue. Some studies have suggested that these tissues share more in common with the sinoatrial nodal myocytes, displaying higher diastolic calcium contents and propensity to spontaneous depolarization. Furthermore, the PV component exhibits increased conduction abnormalities, a higher incidence of delayed after depolarizations and larger late sodium and intracellular and sarcoplasmic reticulum Ca++ contents, but a smaller inward rectifier potassium currents and a reduced resting membrane potential. The posterior wall and the PV myocytes are also characterized by shorter action potential durations and slower phase 0 upstroke velocities. As such, the PV component is believed to be the site of collision of activation wave fronts as they sweep across the left atrial dome. Along these lines, prior Investigators have found this region of the left atrium to be responsible for 80% of high-frequency rotors in an isolated sheep heart model. Similarly, mapping in humans often localizes stable rotors or focal sources as well as complex fractionated electrograms in the posterior wall and the left atrial roof. The PV component has in fact been shown to be a common source of triggers accounting for up to ~40% of non-PV triggers in patients with AF.

Lastly, the PV component is also the site of the main autonomic ganglionic plexi related to the left atrial dome (i.e., the superior left atrial ganglionated plexus) which is believed to modulate extrinsic cardiac innervation and facilitate the occurrence of AF in a hyperactive autonomic state. As such, it is believed that catheter ablation of the PV component also greatly attenuates the input of these plexi to the PVs, interrupting the vagosympathetic input to the ligament of Marshall and the inferior left ganglionated plexus which have been highly implicated in the pathogenesis of AF.

Being tested
Cryoballoon ablation for the treatment of atrial fibrillation
Keywords
Cryoballoon, Pulmonary vein isolation, Posterior wall isolation, Paroxysmal atrial fibrillation
Medical subject headings
Atrial Fibrillation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Cryoballoon ablation for the treatment of atrial fibrillationProcedure or surgery

    Cryoballoon ablation for the treatment of atrial fibrillation

Study groups in NCT05296824
Study groupRoleWhat they receive
Pulmonary vein isolation (PVI) onlyPatients with symptomatic paroxysmal atrial fibrillation who received cryoballoon pulmonary vein isolation (PVI) only
Receives: Procedure: Cryoballoon ablation for the treatment of atrial fibrillation
Pulmonary vein isolation (PVI) with posterior wall isolation (PWI)Patients with symptomatic paroxysmal atrial fibrillation who received cryoballoon pulmonary vein isolation (PVI) with posterior wall isolation (PWI)
Receives: Procedure: Cryoballoon ablation for the treatment of atrial fibrillation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants With Recurrent Atrial Fibrillation

    The recurrence of atrial fibrillation following PVI+PWI versus PVI alone using cryoballoon ablation in patients with symptomatic paroxysmal atrial fibrillation during long-term follow-up greater than 3 years.

    Measured: 56 months

Secondary outcomes (1)
  1. Number of Participants With Recurrence of All Atrial Arrhythmias

    The recurrence of all atrial arrhythmias following PVI+PWI versus PVI alone using cryoballoon ablation in patients with symptomatic paroxysmal atrial fibrillation during long-term follow-up greater than 3 years.

    Measured: 56 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Mar 2022
  2. Study start1 Jan 2014
  3. Primary completion31 Aug 2018
  4. Study completion31 Dec 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Retrospective
Enrolment
320 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05296824
Sponsor's protocol ID
IMPPROVE-PAF
Status last verified
Oct 2025
First submitted
16 Mar 2022
Last updated
5 Nov 2025
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, Garrigue S, Le Mouroux A, Le Metayer P, Clementy J. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998 Sep 3;339(10):659-66. doi: 10.1056/NEJM199809033391003.

    PubMed 9725923
  • Kuniss M, Pavlovic N, Velagic V, Hermida JS, Healey S, Arena G, Badenco N, Meyer C, Chen J, Iacopino S, Anselme F, Packer DL, Pitschner HF, Asmundis C, Willems S, Di Piazza F, Becker D, Chierchia GB; Cryo-FIRST Investigators. Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation. Europace. 2021 Jul 18;23(7):1033-1041. doi: 10.1093/europace/euab029.

    PubMed 33728429
  • Aryana A, Kenigsberg DN, Kowalski M, Koo CH, Lim HW, O'Neill PG, Bowers MR, Hokanson RB, Ellenbogen KA; Cryo-DOSING Investigators. Verification of a novel atrial fibrillation cryoablation dosing algorithm guided by time-to-pulmonary vein isolation: Results from the Cryo-DOSING Study (Cryoballoon-ablation DOSING Based on the Assessment of Time-to-Effect and Pulmonary Vein Isolation Guidance). Heart Rhythm. 2017 Sep;14(9):1319-1325. doi: 10.1016/j.hrthm.2017.06.020. Epub 2017 Jun 15.

    PubMed 28625929
  • Kis Z, Muka T, Franco OH, Bramer WM, De Vries LJ, Kardos A, Szili-Torok T. The Short and Long-Term Efficacy of Pulmonary Vein Isolation as a Sole Treatment Strategy for Paroxysmal Atrial Fibrillation: A Systematic Review and Meta-Analysis. Curr Cardiol Rev. 2017;13(3):199-208. doi: 10.2174/1573403X13666170117125124.

    PubMed 28124593
  • Reddy VY, Neuzil P, d'Avila A, Laragy M, Malchano ZJ, Kralovec S, Kim SJ, Ruskin JN. Balloon catheter ablation to treat paroxysmal atrial fibrillation: what is the level of pulmonary venous isolation? Heart Rhythm. 2008 Mar;5(3):353-60. doi: 10.1016/j.hrthm.2007.11.006. Epub 2007 Nov 7.

    PubMed 18313591
  • Mesquita J, Cavaco D, Ferreira AM, Costa FM, Carmo P, Morgado F, Mendes M, Adragao P. Very long-term outcomes after a single catheter ablation procedure for the treatment of atrial fibrillation-the protective role of antiarrhythmic drug therapy. J Interv Card Electrophysiol. 2018 Jun;52(1):39-45. doi: 10.1007/s10840-018-0340-4. Epub 2018 Mar 6.

    PubMed 29511973
  • McLellan AJ, Ling LH, Azzopardi S, Lee GA, Lee G, Kumar S, Wong MC, Walters TE, Lee JM, Looi KL, Halloran K, Stiles MK, Lever NA, Fynn SP, Heck PM, Sanders P, Morton JB, Kalman JM, Kistler PM. A minimal or maximal ablation strategy to achieve pulmonary vein isolation for paroxysmal atrial fibrillation: a prospective multi-centre randomized controlled trial (the Minimax study). Eur Heart J. 2015 Jul 21;36(28):1812-21. doi: 10.1093/eurheartj/ehv139. Epub 2015 Apr 28.

    PubMed 25920401
  • Reissmann B, Budelmann T, Wissner E, Schluter M, Heeger CH, Mathew S, Maurer T, Lemes C, Fink T, Rillig A, Santoro F, Riedl J, Ouyang F, Kuck KH, Metzner A. Five-year clinical outcomes of visually guided laser balloon pulmonary vein isolation for the treatment of paroxysmal atrial fibrillation. Clin Res Cardiol. 2018 May;107(5):405-412. doi: 10.1007/s00392-017-1199-6. Epub 2017 Dec 28.

    PubMed 29285621
  • Aryana A, Baker JH, Espinosa Ginic MA, Pujara DK, Bowers MR, O'Neill PG, Ellenbogen KA, Di Biase L, d'Avila A, Natale A. Posterior wall isolation using the cryoballoon in conjunction with pulmonary vein ablation is superior to pulmonary vein isolation alone in patients with persistent atrial fibrillation: A multicenter experience. Heart Rhythm. 2018 Aug;15(8):1121-1129. doi: 10.1016/j.hrthm.2018.05.014.

    PubMed 30060879
  • Elbatran AI, Anderson RH, Mori S, Saba MM. The rationale for isolation of the left atrial pulmonary venous component to control atrial fibrillation: A review article. Heart Rhythm. 2019 Sep;16(9):1392-1398. doi: 10.1016/j.hrthm.2019.03.012. Epub 2019 Mar 16.

    PubMed 30885736
  • Clarke JD, Piccini JP, Friedman DJ. The role of posterior wall isolation in catheter ablation of persistent atrial fibrillation. J Cardiovasc Electrophysiol. 2021 Sep;32(9):2567-2576. doi: 10.1111/jce.15164. Epub 2021 Jul 21.

    PubMed 34258794
  • Aryana A, Su W, Kuniss M, Okishige K, de Asmundis C, Tondo C, Chierchia GB. Segmental nonocclusive cryoballoon ablation of pulmonary veins and extrapulmonary vein structures: Best practices III. Heart Rhythm. 2021 Aug;18(8):1435-1444. doi: 10.1016/j.hrthm.2021.04.020. Epub 2021 Apr 24.

    PubMed 33905811
  • Bisignani A, Overeinder I, Kazawa S, Iacopino S, Cecchini F, Miraglia V, Osorio TG, Boveda S, Bala G, Mugnai G, Monaco C, Stroker E, Brugada P, Sieira J, Galli A, de Asmundis C, Chierchia GB. Posterior box isolation as an adjunctive ablation strategy with the second-generation cryoballoon for paroxysmal atrial fibrillation: a comparison with standard cryoballoon pulmonary vein isolation. J Interv Card Electrophysiol. 2021 Aug;61(2):313-319. doi: 10.1007/s10840-020-00812-z. Epub 2020 Jul 6.

    PubMed 32632544
  • Mun HS, Joung B, Shim J, Hwang HJ, Kim JY, Lee MH, Pak HN. Does additional linear ablation after circumferential pulmonary vein isolation improve clinical outcome in patients with paroxysmal atrial fibrillation? Prospective randomised study. Heart. 2012 Mar;98(6):480-4. doi: 10.1136/heartjnl-2011-301107. Epub 2012 Jan 27.

    PubMed 22285969
  • Kim TH, Park J, Park JK, Uhm JS, Joung B, Hwang C, Lee MH, Pak HN. Linear ablation in addition to circumferential pulmonary vein isolation (Dallas lesion set) does not improve clinical outcome in patients with paroxysmal atrial fibrillation: a prospective randomized study. Europace. 2015 Mar;17(3):388-95. doi: 10.1093/europace/euu245. Epub 2014 Oct 21.

    PubMed 25336665

Questions about this trial

What is this clinical trial studying?

An observational study of Paroxysmal Atrial Fibrillation, run by Sacramento EP Research at 4 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 5 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 5 Nov 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants With Recurrent Atrial Fibrillation (time frame: 56 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05296824, which also lists 21 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Nov 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in